HC Wainwright started coverage on shares of Audentes Therapeutics (NASDAQ:BOLD) in a research report sent to investors on Wednesday, Marketbeat.com reports. The brokerage issued a buy rating and a $37.00 price target on the biotechnology company’s stock.

Several other analysts also recently commented on the stock. BidaskClub raised shares of Audentes Therapeutics from a buy rating to a strong-buy rating in a report on Wednesday. BMO Capital Markets assumed coverage on shares of Audentes Therapeutics in a report on Tuesday, December 5th. They issued an outperform rating and a $35.00 price objective on the stock. ValuEngine downgraded shares of Audentes Therapeutics from a hold rating to a sell rating in a report on Friday, December 1st. Zacks Investment Research downgraded shares of Audentes Therapeutics from a hold rating to a sell rating in a report on Friday, November 17th. Finally, Leerink Swann reaffirmed an outperform rating and issued a $29.00 price objective (up from $22.00) on shares of Audentes Therapeutics in a report on Wednesday, November 15th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. The stock currently has an average rating of Buy and an average target price of $29.38.

Audentes Therapeutics (NASDAQ BOLD) traded up $0.03 during trading hours on Wednesday, reaching $31.00. 133,822 shares of the company’s stock traded hands, compared to its average volume of 234,495. The stock has a market cap of $926.41 and a P/E ratio of -8.91. Audentes Therapeutics has a 12 month low of $13.90 and a 12 month high of $33.43.

Audentes Therapeutics (NASDAQ:BOLD) last released its earnings results on Tuesday, November 14th. The biotechnology company reported ($0.88) earnings per share for the quarter, hitting the consensus estimate of ($0.88). analysts predict that Audentes Therapeutics will post -3.52 EPS for the current year.

In related news, Director Louis G. Lange sold 18,000 shares of the business’s stock in a transaction on Monday, September 25th. The shares were sold at an average price of $28.32, for a total value of $509,760.00. Following the completion of the transaction, the director now directly owns 453,393 shares in the company, valued at approximately $12,840,089.76. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, major shareholder Orbimed Advisors Llc sold 672,000 shares of the business’s stock in a transaction on Friday, September 29th. The shares were sold at an average price of $28.25, for a total transaction of $18,984,000.00. The disclosure for this sale can be found here. Insiders sold a total of 747,750 shares of company stock worth $21,112,750 over the last ninety days. Insiders own 47.30% of the company’s stock.

Institutional investors and hedge funds have recently bought and sold shares of the stock. SG Americas Securities LLC acquired a new position in shares of Audentes Therapeutics in the 3rd quarter valued at $143,000. Nationwide Fund Advisors lifted its stake in shares of Audentes Therapeutics by 288.9% in the 2nd quarter. Nationwide Fund Advisors now owns 8,594 shares of the biotechnology company’s stock valued at $164,000 after purchasing an additional 6,384 shares during the period. State of Wisconsin Investment Board acquired a new position in shares of Audentes Therapeutics in the 2nd quarter valued at $210,000. Rhumbline Advisers acquired a new position in shares of Audentes Therapeutics in the 2nd quarter valued at $252,000. Finally, Virtu KCG Holdings LLC acquired a new position in shares of Audentes Therapeutics in the 2nd quarter valued at $257,000. Hedge funds and other institutional investors own 78.95% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This story was first posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this story on another website, it was illegally stolen and republished in violation of United States and international trademark and copyright law. The legal version of this story can be accessed at https://theolympiareport.com/2017/12/23/audentes-therapeutics-bold-research-coverage-started-at-hc-wainwright.html.

Audentes Therapeutics Company Profile

Audentes Therapeutics, Inc is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).

Analyst Recommendations for Audentes Therapeutics (NASDAQ:BOLD)

Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.